Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Comparing catheter-directed thrombectomy to thrombolysis for high-risk pulmonary embolism

Official title: 'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL

Run by Leiden University Medical Center · NCT06833827 · Data updated 2026-11-12

This study is testing if a new procedure called catheter-directed thrombectomy can help people with high-risk pulmonary embolism do better than the standard treatment of full-dose thrombolysis.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment111 (estimated)
SponsorLeiden University Medical Center
Academic / other
Locations1 site (Leiden, South Holland)
StatusRecruiting
StartedFebruary 2025
Main results expectedJanuary 2028
Study endsJanuary 2029
Registry record updatedFebruary 19, 2025
Trial IDNCT06833827 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adult patients with confirmed acute pulmonary embolism who are at high risk for mortality.

Probably not a fit

Patients with low-risk pulmonary embolism or those who do not meet the inclusion criteria will likely not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

TORPEDO-NL is an investigator-initiated, multicentre, open-label, randomized controlled trial designed to evaluate the effectiveness of catheter-directed thrombectomy (CDT) compared to full-dose systemic thrombolysis in patients with high-risk pulmonary embolism (PE). The study aims to determine if CDT can reduce mortality and adverse events associated with treatment, given the significant risks of bleeding with thrombolysis. Patients will be closely monitored for outcomes related to mortality and treatment failure, providing critical data on the safety and efficacy of this alternative approach.

Why it matters

Potential benefit: If successful, this study could provide a safer and more effective treatment option for patients with high-risk pulmonary embolism.

How similar studies have gone: While catheter-directed thrombectomy is a promising alternative, randomized trials evaluating its safety and efficacy in high-risk patients are currently lacking, making this approach novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Adult patients with confirmed acute PE, i.e. contrast filling defect in a lobar or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA), and/or obstructive shock with echocardiographic confirmed dilatation of the right ventricle and a congested vena cava inferior, both with/without echocardiographic signs of clot in transit or deep vein thrombosis of the leg.
2. High risk for mortality, i.e.

   1. post cardiac arrest (after temporary need for cardiopulmonary resuscitation), OR
   2. obstructive shock (systolic blood pressure \<90 mmHg and signs of end-organ hypoperfusion (e.g. elevated lactate levels \>2 mmol/l) or the need for vasopressors (adrenalin or noradrenalin) to maintain an adequate blood pressure), OR
   3. persistent hypotension (systolic blood pressure \<90 mmHg or systolic blood pressure drop ≥40 mmHg for at least 15 minutes) not caused by new onset arrhythmia, hypovolemia, or sepsis, OR
   4. abnormal RV function on transthoracic echocardiography or CTPA AND elevated cardiac troponin levels AND respiratory failure defined as hypoxemia (SaO2 \<90%) refractory to O2 supplementation by nasal cannula or Venturi mask, requiring full face mask O2 supplementation (100% FiO2), high-flow nasal O2, or (non-)invasive mechanical ventilation.
3. CDT available and technically feasible so as to allow for a randomization-to-needle time of 60 minutes or less.

Exclusion Criteria:

1. "Catastrophic PE", i.e. ongoing cardiac arrest and/or need for extracorporeal cardiopulmonary resuscitation (ECPR) and/or immediate indication for venoarterial extracorporeal membrane oxygenation (VA-ECMO) as judged by the responsible physician(s)
2. Glascow Coma Scale \<8 following resuscitation for cardiac arrest
3. Alternative diagnosis than acute PE contributing largely to the acute hemodynamic and/or respiratory failure, e.g. sepsis, COPD GOLD 3 or 4, or known heart failure with NYHA Functional Classification of 4, as judged by the treating physician.
4. A known "do not admit to the ICU" or "do not resuscitate" directive
5. An absolute contraindication to systemic thrombolysis, i.e.

   * History of hemorrhagic stroke
   * Ischemic stroke in past 6 months
   * Central nervous system neoplasm
   * Major trauma, major surgery or major head injury in past 3 weeks (note: mild external laceration of the head after, e.g. syncope, does not count as major head injury, especially when a CT scan of the head shows no hematoma)
   * Active bleeding, life-threatening or into a critically organ/area; OR known severe bleeding diathesis with previous bleeding fulfilling these criteria
6. Reperfusion therapy (systemic thrombolysis, surgical thrombectomy or CDT/other catheter directed therapy), or placement of a non-retrieved inferior vena cava filter for acute pulmonary embolism in the past 3 months
7. Thrombus in transit through a patent foramen ovale.
8. Known chronic thromboembolic pulmonary hypertension (CTEPH), or strong suspicion of CTEPH based on pre-existing clinical findings and combinations of signs of PE chronicity on echocardiography and/or CTPA.
9. Known hypersensitivity to systemic thrombolysis, heparin, or to any of the excipients
10. If, in the Investigator's opinion, or after consultation with the local PERT-team or EC-members, the patient is not appropriate for thrombectomy
11. Chronic use of full-dose oral or parenteral anticoagulation before presentation.
12. Pregnancy
13. Current participation in another study that would interfere with participation in this study
14. Previous enrolment in this study
15. Refusal of deferred consent by the next of kin or by the patient himself to use the data. Deferred consent will not be asked to relatives of patients who die in scene, but are included in the study.

Where it's running

  • Leiden University Medical Centre
    Leiden, South Holland, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.